The Evolution of the Biomedical Paradigm in Oncology: Implications for Cancer Therapy

  • Gilberto Corbellini
  • Chiara Preti
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 610)

According to the view of Harold Varmus, it is time for “changes in the culture of oncology” (Varmus 2006, 1165). The former NIH director and Nobel prize recipient for physiology and medicine for the discovery of oncogenes believes that “during most of the past 50 years, pharmaceutical chemistry continued to serve cancer patients much more effectively than did cancer biology.” He argues that, as a consequence of the strategy adopted, “laboratory-based investigations into the nature of cancer cells and clinical efforts to control cancer often seemed to inhabit separate worlds” (Varmus, 2006, 1162). So he points out that “the new era in cancer research” needs “stronger working relationships between bench scientists and their clinical colleagues, between oncologists in academia and those in community hospitals, and between oncologists and other physicians.” Moreover “new training programs” should “provide graduate students in the basic sciences with an opportunity to understand the dilemmas posed by cancer as a human disease” (Varmus 2006, 1165).


Nuclear Transplantation Hereditary Cancer Nitrogen Mustard Magic Bullet Epistemological Evolution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson, G. R. (2001) Genomic instability and cancer. Current Science. 81, 501–507.Google Scholar
  2. Armitage, P. and Doll, R. (1954) The Age Distribution of Cancer and a Multistage Theory of Carcinogenesis. British Journal of Cancer. 8, 9.Google Scholar
  3. Balmain, A. (2001) Cancer genetics: from Boveri and Mendel to microarrays. Nature Reviews Cancer 1, 77–82.PubMedCrossRefGoogle Scholar
  4. Berenbluem, I. and Shubik, P. (1949) An Experimental Study of the Initiating Stage of Carcinogenesis, and a Re-Examination of the Somatic Cell Mutation Theory of Cancer. British Journal of Cancer. 3, 109–18.Google Scholar
  5. Berenblum, I. and Shubik, P. (1947) A New, Quantitative Approach to the Study of the Stages of Chemical Carcinogenesis in the Mouse’s Skin. British Journal of Cancer 1, 383–91.PubMedGoogle Scholar
  6. Boveri, T. H. (1914) Zur Frage der Enstehung maligner Tumoren. Gustav Fisher, Jena.Google Scholar
  7. Breivik, J. and Gaudernack, G. (1999) Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv. Cancer Research 76, 187–212.CrossRefGoogle Scholar
  8. Burdette, W. J. (1955) The Significance of Mutation in Relation to the Origin of Tumors: A Review. Cancer Res 15, 201–226.PubMedGoogle Scholar
  9. Cahill, D. P.; Kinzler, K.W.; Vogelstein, B., and Lengauer, C. (1999) Genetic instability and Darwinian selection in tumors. Trends Cell Biol. 12, M57–60.CrossRefGoogle Scholar
  10. Comings, D. E. (1973) A General Theory of Carcinogenesis. Proc. Natl. Acad. Sci. 70, 3324–28.PubMedCrossRefGoogle Scholar
  11. Corbellini G. (2007) EBM. Evolution Based Medicine. Il darwinismo nelle scienze biomediche. Laterza, Roma-Bari.Google Scholar
  12. Dobzhansky, T. (1973) Nothing in Biology Makes Sense Except in the Light of Evolution. The American Biology Teacher 35, 125–129.Google Scholar
  13. Drews, J. (2006) Case histories, magic bullets and the state of drug discovery. Nature Rev. Drug Discovery 5, 635–640.CrossRefGoogle Scholar
  14. Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759–767.PubMedCrossRefGoogle Scholar
  15. Ferrara, N.; Hillan, K. J.; Gerber, H. P. and Novotny, W. (2004) Discovery and development of bevacizumab, and anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery 3, 391–400.CrossRefGoogle Scholar
  16. Folkman, J. and Kalluri, R. (2004) Cancer without disease. Nature 427, 787.PubMedCrossRefGoogle Scholar
  17. Foulds, L. (1949) Mammary tumors in hybrid mice; growth and progression of spontaneous tumors. British Journal of Cancer 3, 345–75.PubMedGoogle Scholar
  18. Foulds, L. (1954) The experimental study of tumor progression: a review. Cancer Research 14, 327–339.PubMedGoogle Scholar
  19. Foulds, L. (1956) The histologic analysis of mammary tumors of mice. 2. The histology of responsiveness and progression – The origins of tumors. Journal of the National Cancer Institute 17, 713–756.Google Scholar
  20. Foulds, L. (1958) The natural history of cancer. Journal of Chronic Diseases 8, 2–37.PubMedCrossRefGoogle Scholar
  21. Foulds, L. (1969) Neoplastic Development. Academic Press, New York.Google Scholar
  22. Friend, S. H.; Bernards, R.; Rogelj, S., et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–46.PubMedCrossRefGoogle Scholar
  23. Gardner, M. B. (1994) The Virus Cancer Program of the 1970s: a personal and retrospective view. Laboratory Animals Science 44, 101–13.Google Scholar
  24. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57–70.PubMedCrossRefGoogle Scholar
  25. Harris, H.; Miller, O. J.; Klein, G.; Worst, P. and, Tachibana, T. (1969) Suppression of malignancy by cell fusion. Nature, 223, 363–8.PubMedCrossRefGoogle Scholar
  26. Hasegawa, Y.; Ando, Y.; Ando, M.; Hashimoto, N.; Imaizumi, K. and Shimokata, K. (2006) Pharmacogenetic Approach for Cancer Treatment-Tailored Medicine in Practice. Ann. N. Y. Acad. Sci. 1086, 223–232.PubMedCrossRefGoogle Scholar
  27. Hochedlinger, K.; Blelloch, R.; Brennan, C.; Yamada, Y.; Kim, M.; Chin, L. and Jaenisch, R. (2004) Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875–1885.PubMedCrossRefGoogle Scholar
  28. Horrobin, D. F. (2003) Modern biomedical research: an internally self-consistent universe with little contact with medical reality. Nature Rev. Drug Discovery 2, 151–154.CrossRefGoogle Scholar
  29. Huebner, R. J. and Todaro, G. J. (1969) Oncogenes of RNA tumor viruses as determinants of Cancer, Proc. Natl. Acad. Sci. 64, 1087–94.PubMedCrossRefGoogle Scholar
  30. Knudson, A. G. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. 68, 820–823.PubMedCrossRefGoogle Scholar
  31. Knudson, A. G. (1971) Mutation and Cancer: Statistical Study of Retinoblastoma. Proc. Nat. Acad. Sci. 68, 820–23.PubMedCrossRefGoogle Scholar
  32. Knudson, A. G. (1983) Model hereditary cancers of man. Pro. Nucleic Acid Res. Mol. Biol. 29, 17–25.CrossRefGoogle Scholar
  33. Knudson, A. G. (1985) Hereditary Cancer, Oncogenes, and Antioncogenes. Cancer Research, 45, 1437–43.PubMedGoogle Scholar
  34. Knudson, A. G. (2005) A personal 60-Year Tour of Genetics and Medicine. Annu. Rev. Genomics Hum. Genet. 6, 1–14.PubMedCrossRefGoogle Scholar
  35. Koufos, A.; Hansen, M. F.; Copeland, N. G.; Jenkins, N. A.; Lampkin, B. C. and Cavenee, W. K. (1986) Loss of heterozygosity in three embryonal tumors suggests a common pathogenetic mechanism. Nature 316, 330–34.CrossRefGoogle Scholar
  36. Leaf, C. (2004) Why we’re losing the war on cancer (and how to win it). Fortune 149(6), 76–82, 84–6, 88.PubMedGoogle Scholar
  37. Michor, F.; Iwasa, Y. and Nowak, M. A. (2004) Dynamics of cancer progression. Nature Review Cancer, 4, 197–205.CrossRefGoogle Scholar
  38. Michor, F.; Nowak, M. A. and Iwasa, Y. (2006) Evolution of resistance to cancer therapy. Current Pharmaceutical Design 12, 261–271.PubMedCrossRefGoogle Scholar
  39. Moss, L. (2003) What Genes Can’t Do. The MIT Press, Cambridge (MA).Google Scholar
  40. Nowell, P. C. (1976) The clonal evolution of tumor cell populations. Science 194, 23–8.PubMedCrossRefGoogle Scholar
  41. Rous, P. (1943) The Nearer Causes of Cancer JAMA 122, 573–81.Google Scholar
  42. Porter, R. (1997) The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present. Harper Collins, London.Google Scholar
  43. Schimke, R. T.; Kaufman, R. J.; Alt, F. W. and Kellems, R. F. (1978) Gene amplification and drug resistance in cultured murine cells. Science 202, 1051–5.PubMedCrossRefGoogle Scholar
  44. Searls, D. B. (2003) Pharmacophylogenomics: genes, evolution and drug targets. Nature Rev. Drug Discovery 2, 613–623.CrossRefGoogle Scholar
  45. Smithers, D. W. (1962) An attack on cytologism. The Lancet 1, 493–9.CrossRefGoogle Scholar
  46. Stehelin, D.; Varmus, H. E. and Bishop, M. J. (1976) DNA related to the Transforming Gene(s) of Avian Sarcoma Viruses Is Present in Normal Avian DNA. Nature 260, 170–3.PubMedCrossRefGoogle Scholar
  47. Temin, H. M. (1971) The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J Natl Cancer Inst. 46(2), 3–7.PubMedGoogle Scholar
  48. Thagard, P. (1999) How Scientists Explain Disease. Princeton University Press, Princeton.Google Scholar
  49. Varmus, H. (2006) The New Era in Cancer Research. Science 312, 1162–1165.PubMedCrossRefGoogle Scholar
  50. Vineis, P. and Berwick, M. (2006) The population dynamics of cancer: a Darwinian perspective. Int. J. Epidemiol. 35, 1151–9.PubMedCrossRefGoogle Scholar
  51. Weinberg, R. (2006) The Biology of Cancer. Garland Science, New York.Google Scholar
  52. Weiss, L. (2000). Cancer cell heterogeneity. Cancer and Metastasis Reviews 19, 345–350.CrossRefGoogle Scholar
  53. Wicha, M. S.; Liu, S. and Dontu, G. (2006). Cancer Stem Cells: An Old Idea – A Paradigm Shift. Cancer Research 66, 1883–1890.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Gilberto Corbellini
  • Chiara Preti

There are no affiliations available

Personalised recommendations